Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Lancet Gastroenterol Hepatol
    September 2025
  1. VISSER E, Buskens CJ
    Appendicectomy for ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:789-790.
    >> Share

  2. SCARPA M, Castagliuolo I, Kotsafti A, Angriman I, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788.
    >> Share

  3. BRONZE S, Agrawal M, Rodriguez-Lago I, Colombel JF, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788-789.
    >> Share

    July 2025
  4. DANESE S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, et al
    Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
    Lancet Gastroenterol Hepatol. 2025 Jul 21:S2468-1253(25)00129.
    >> Share

  5. YOGAKANTHI S, Raine T
    Progress in validation of treatment-response biomarkers in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00138.
    >> Share

  6. JOUSTRA VW, Li Yim AYF, Henneman P, Hageman I, et al
    Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00102.
    >> Share

    June 2025
  7. BOUHNIK Y, Mary JY
    A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00127.
    >> Share

  8. MA C, Khanna R, Maguire BR, Zou G, et al
    Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00093.
    >> Share

  9. PANACCIONE R, Vermeire S, Danese S, Higgins PDR, et al
    Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Lancet Gastroenterol Hepatol. 2025;10:507-519.
    >> Share

  10. NOOR NM, Parkes M, Raine T
    U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:492-493.
    >> Share

  11. NEURATH MF, Artis D, Becker C
    The intestinal barrier: a pivotal role in health, inflammation, and cancer.
    Lancet Gastroenterol Hepatol. 2025;10:573-592.
    >> Share

    May 2025
  12. FEAGAN BG, Sands BE, Siegel CA, Dubinsky MC, et al
    Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00071.
    >> Share

  13. LINDSAY J
    Tulisokibart shows promise for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00103.
    >> Share

    April 2025
  14. HANNA LN, Munster LJ, Joshi S, Wendelien van der Bilt JD, et al
    Isolated perianal Crohn's disease: a systematic review and expert consensus proposing novel diagnostic criteria and management advice.
    Lancet Gastroenterol Hepatol. 2025 Apr 29:S2468-1253(25)00007.
    >> Share

  15. UKASHI O, Ben-Horin S
    Appendicectomy: a novel treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00065.
    >> Share


  16. Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00026.
    >> Share

  17. HONAP S, Agrinier N, Torres J, Croitoru K, et al
    Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
    Lancet Gastroenterol Hepatol. 2025 Apr 2:S2468-1253(24)00439.
    >> Share

    March 2025
  18. SHENOY S, Jena A, Levinson C, Sharma V, et al
    Inflammatory bowel disease in south Asia: a scoping review.
    Lancet Gastroenterol Hepatol. 2025;10:259-274.
    >> Share

  19. D'HAENS G
    Vedolizumab for prevention of recurrence of Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:194-195.
    >> Share

  20. HAMMOUDI N, Allez M
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193.
    >> Share

  21. NGUYEN A, Li Wai Suen CFD, Srinivasan A, Segal J, et al
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193-194.
    >> Share

    February 2025
  22. TEMIDO MJ, Honap S, Jairath V, Vermeire S, et al
    Overcoming the challenges of overtreating and undertreating inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Feb 4:S2468-1253(24)00355.
    >> Share

  23. NOOR NM, Estevinho MM, Solitano V, Yuan Y, et al
    Applying the estimand framework to inflammatory bowel disease clinical trials.
    Lancet Gastroenterol Hepatol. 2025 Feb 3:S2468-1253(25)00004.
    >> Share

    January 2025
  24. SANDS BE, Panaccione R, D'Haens G, Schreiber S, et al
    Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386.
    >> Share

  25. ATREYA R, Neurath MF
    No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00397.
    >> Share

  26. ATIA O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, et al
    Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2025 Jan 6:S2468-1253(24)00319.
    >> Share

  27. LI WAI SUEN CFD, Choy MC, Con D, De Cruz P, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:19.
    >> Share

  28. HOFFERT Y, Ferrante M, Verstockt B, Dreesen E, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:18-19.
    >> Share

  29. COMAN D, Battat R
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:17-18.
    >> Share

  30. VAN DER DOES DE WILLEBOIS EML, Bemelman WA, Buskens CJ
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:16-17.
    >> Share

  31. COFFEY JC, Li Y, Walsh D, Connelly TM, et al
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15.
    >> Share

  32. KELM M, Flemming S
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15-16.
    >> Share

  33. DUAN M, Li Y
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14-15.
    >> Share

  34. YADAV A
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14.
    >> Share

    December 2024
  35. AINSWORTH MA
    Does filgotinib work for Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00304.
    >> Share

  36. VERMEIRE S, Schreiber S, Rubin DT, D'Haens G, et al
    Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00272.
    >> Share

    November 2024
  37. D'HAENS G, Taxonera C, Lopez-Sanroman A, Nos P, et al
    Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317.
    >> Share

  38. MULLIGAN RJ, Lamb CA
    Vedolizumab prophylaxis against postoperative Crohn's disease recurrence.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00352.
    >> Share

  39. ANDERSEN V, Pingel J, Sofelt HL, Hikmat Z, et al
    Sex and gender in inflammatory bowel disease outcomes and research.
    Lancet Gastroenterol Hepatol. 2024;9:1041-1051.
    >> Share

  40. GOMOLLON F
    Do placebos harm patients in IBD trials?
    Lancet Gastroenterol Hepatol. 2024;9:970-972.
    >> Share

    October 2024
  41. LU C, Rosentreter R, Parker CE, Remillard J, et al
    International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
    Lancet Gastroenterol Hepatol. 2024 Oct 21:S2468-1253(24)00265.
    >> Share

    September 2024
  42. GROS B, Blackwell J, Segal J, Black CJ, et al
    Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00233.
    >> Share

  43. DIN S, Segal J, Blackwell J, Gros B, et al
    Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00264.
    >> Share

  44. KEDIA S, Ahuja V
    Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00229.
    >> Share

  45. CHOY MC, Li Wai Suen CFD, Con D, Boyd K, et al
    Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00200.
    >> Share

    July 2024
  46. NOOR NM, Sebastian S, Parkes M, Raine T, et al
    The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 Jul 30:S2468-1253(24)00225.
    >> Share

  47. VAN DER DOES DE WILLEBOIS EML, Bellato V, Duijvestein M, van der Bilt JDW, et al
    Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00097.
    >> Share

  48. CLICK B, Holubar SD
    Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00186.
    >> Share

  49. CHEN R, Zhang S
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:592.
    >> Share

  50. NOOR NM, Lee JC, Bond S, Parkes M, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply.
    Lancet Gastroenterol Hepatol. 2024;9:592-594.
    >> Share

  51. BORKAR V, Lunagariya Y, Chopra S, Sasikumar D, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591.
    >> Share

  52. SATSANGI J, Nowak J, Kalla R, Colombel JF, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591-592.
    >> Share

  53. BOURGONJE AR, Visschedijk MC, Festen EAM, Weersma RK, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:590-591.
    >> Share

    June 2024
  54. GUPTA A, Guisado D, Ricart E, Colombel JF, et al
    Haematopoietic stem-cell transplantation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024;9:499-500.
    >> Share

    May 2024
  55. IACUCCI M, Santacroce G, Zammarchi I, Maeda Y, et al
    Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 May 14:S2468-1253(24)00053.
    >> Share

  56. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
    Microbiota therapeutics for inflammatory bowel disease: the way forward.
    Lancet Gastroenterol Hepatol. 2024;9:476-486.
    >> Share

  57. FUMERY M, Buisson A
    Has the time come for a systematic top-down approach in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024;9:394-395.
    >> Share

    April 2024
  58. PARKES GC, Hedin CRH
    PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
    >> Share

  59. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
    Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
    >> Share

    March 2024
  60. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
    Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
    Lancet Gastroenterol Hepatol. 2024;9:263-272.
    >> Share

  61. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
    Acute severe ulcerative colitis management: unanswered questions and latest insights.
    Lancet Gastroenterol Hepatol. 2024;9:251-262.
    >> Share

    February 2024
  62. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    >> Share

  63. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    >> Share

  64. CICCOCIOPPO R, Gaspar L
    Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
    >> Share

  65. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
    Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
    >> Share

    January 2024
  66. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
    Promoting equity in inflammatory bowel disease: a global approach to care.
    Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
    >> Share

    December 2023
  67. FUMERY M, Buisson A
    Guselkumab in Crohn's disease: the IL-23 race continues.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
    >> Share

  68. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
    Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
    >> Share

    October 2023
  69. DIBLEY L, Duffy M
    Inflammatory bowel disease health care for LGTBQIA+ patients.
    Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
    >> Share

  70. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
    Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
    >> Share

  71. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    >> Share

    September 2023
  72. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
    Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
    >> Share

  73. ATREYA R, Neurath MF
    Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
    >> Share

    August 2023
  74. SENIOR K
    Surgery in Crohn's disease: patients need MDT-led holistic care.
    Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
    >> Share

  75. SHIN A
    Psychological therapies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
    >> Share

  76. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
    Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
    >> Share

    July 2023
  77. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
    Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
    Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
    >> Share

    May 2023
  78. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    >> Share

  79. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    >> Share

  80. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    >> Share

  81. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    >> Share

  82. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    >> Share

  83. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    >> Share

  84. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    >> Share

    April 2023
  85. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    >> Share

    March 2023
  86. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    >> Share

  87. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    >> Share

  88. BURISCH J, Zhao M, Odes S, De Cruz P, et al
    The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016